i
Post-licensure safety surveillance of 20-valent pneumococcal conjugate vaccine (PCV20) among U.S. adults in the Vaccine Adverse Event Reporting System (VAERS)
-
February 29, 2024
Series: ACIP meeting Influenza
[PDF-545.50 KB]
Details:
-
Personal Author:
-
Corporate Authors:
-
Conference Authors:
-
Subjects:
-
Series:
-
Document Type:
-
Name as Subject:
-
Genre:
-
Collection(s):
-
Main Document Checksum:urn:sha256:eb80138974766a9988e7702cfe0639eb9814bbac4f6e6413db7f18ff91c260dd
-
File Type:
Supporting Files
-
No Additional Files
More +
Related Documents
-
Personal Author:Self, Wesley H. ;Rouphael, Nadine...February 29, 2024 | ACIP meeting Pneumococcal VaccinesDescription:Funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USAhttps://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2024-...Personal Author:Das, RituparnaFebruary 29, 2024 | ACIP meeting Respiratory Syncytial Virus (RSV) Older Adults VaccineDescription:The safety and efficacy of this investigational RSV vaccine have not been established in any country for any use02-RSV-Adults-Das-508.pdf
More +
You May Also Like
Checkout today's featured content at stacks.cdc.gov